Celgene acquiring cancer drug firm Juno Therapeutics for $9 bn
US biotech firm Celgene on Monday announced a deal to acquire the bio-pharmaceutical company Juno Therapeutics for $9 billion or $87 per share.
Jan 22, 2018
0
3
US biotech firm Celgene on Monday announced a deal to acquire the bio-pharmaceutical company Juno Therapeutics for $9 billion or $87 per share.
Jan 22, 2018
0
3
Celgene Corp. has agreed to pay $280 million to settle a whistleblower lawsuit alleging the pharmaceutical company committed fraud promoting a drug with a notorious history that was re-purposed to treat leprosy and another ...
Jul 26, 2017
0
0
Federal regulators have approved Celgene Inc.'s drug Abraxane to treat late-stage pancreatic cancer.
Sep 7, 2013
0
0
Amgen has agreed to acquire the global rights to Otezla, a drug used for the treatment of psoriasis and psoriatic arthritis, for $13.4 billion in cash, Bristol Myers Squibb said Monday.
Aug 26, 2019
0
2
Cancer drug maker Celgene said it will buy Receptos for $7.32 billion in cash, gaining a drug Receptos is studying as a treatment for multiple sclerosis and ulcerative colitis.
Jul 14, 2015
0
10
In a major step to treat patients living with Myelodysplastic Syndromes (MDS), a group of diseases that affect the bone marrow and blood, Moffitt Cancer Center today announced the development of an innovative investigational ...
Nov 18, 2014
0
0
(HealthDay)—Pomalyst (pomalidomide) has been approved by the U.S. Food and Drug Administration to treat cases of multiple myeloma that have not responded to other therapies.
Feb 9, 2013
0
0